Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions

Pancreatic cancer is one of the most lethal cancers, where curative surgical resections are rare and less than 5% of patients experience long-term survival. Despite numerous clinical trials, improvements in the systemic treatment of this disease have been limited. Gemcitabine, a nucleoside analogue,...

Descripción completa

Detalles Bibliográficos
Autores principales: Spratlin, Jennifer L., Mackey, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840445/
https://www.ncbi.nlm.nih.gov/pubmed/24281217
http://dx.doi.org/10.3390/cancers2042044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840445/
https://www.ncbi.nlm.nih.gov/pubmed/24281217
http://dx.doi.org/10.3390/cancers2042044

Ejemplares similares